JANX Janux Therapeutics, Inc.
Healthcare$14.40-0.83%ClosedMarket Cap: $878.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.97
P/S
40.97
EV/EBITDA
-6.40
DCF Value
$-2.98
FCF Yield
-8.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.1%
Operating Margin
-726.3%
Net Margin
-529.7%
ROE
-11.8%
ROA
-11.1%
ROIC
-16.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.7M | 87.4% | $-34.2M | $-24.4M | $— | — |
| Q4 null | $7.9M | -13.5% | $-42.4M | $-31.9M | $— | — |
| FY null | $10.0M | 79.7% | $-157.7M | $-113.6M | $— | — |
| Q3 null | $10.0M | 95.0% | $-35.3M | $-24.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-45.1M | $-33.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-34.9M | $-23.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-29.0M | $-20.2M | $— | — |
| FY null | $10.6M | 80.5% | $-98.8M | $-69.0M | $— | — |
| Q3 null | $439.0K | 100.0% | $-35.8M | $-28.1M | $— | — |
| Q2 null | $8.9M | 94.3% | $-13.8M | $-6.0M | $— | — |
| Q1 null | $1.3M | 57.5% | $-20.2M | $-14.8M | $— | — |
| Q4 2023 | $2.5M | 78.4% | $-16.1M | $-11.8M | $-0.25 | — |